Posted by Michael Wonder on 17 Apr 2017
Expanding CADTH’s drug review processes to include radiopharmaceuticals
17 April 2017 - In collaboration with the participating jurisdictions, CADTH is pleased to announce that it will accept submissions for radiopharmaceuticals used for therapeutic purposes (i.e., not for diagnostic purposes) for review through the CADTH Common Drug Review and the CADTH pan-Canadian Oncology Drug Review programs effective April 1, 2017.
Applicants/Submitters planning to file a submission or resubmission for a radiopharmaceutical on or after April 1, 2017 to Common Drug Review (CDR) or pan-Canadian Oncology Drug Review (pCODR) must comply with the same procedures, submission requirements, and timelines for a drug as set out by the CDR and pCODR programs.
Consistent with the input and feedback processes for CADTH’s respective drug review programs, stakeholders (e.g., patient groups) will have an opportunity to provide input and feedback on a radiopharmaceutical submission.
